Angiotensinogen

Kahlon, Tanvir; Carlisle, Samantha M.; Mostacero, Diana Otero; Williams, Nina; Trainor, Patrick J.; DeFilippis, Andrew P.

doi:10.1016/j.jchf.2022.06.005

Cited by 15 publications

(13 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To determine the relationship between circulating angiotensinogen levels and sex by HT, an un-adjusted linear model was estimated by regressing levels of angiotensinogen on sex by HT and estradiol levels. This model was then refitted to incorporate other covariates that had univariable R 2 values greater than 0.025 [race/ethnicity, BMI, total cholesterol, high-sensitivity C-reactive protein (hs-CRP), total testosterone, DHEA, and SHBG). Un-adjusted and adjusted linear models set men as the reference group, and each analyte was log-transformed and then scaled to have mean zero and standard deviation 1.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Circulating Levels of Angiotensinogen, Sex, and Hormone Therapy - The Multi-Ethnic Study of Atherosclerosis (MESA)

Lidani,

Trainor,

Buscaglia

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Angiotensinogen, the unique precursor of all angiotensin hormones of the Renin-Angiotensin-Aldosterone System (RAAS), is now a potential target in a novel pharmacological approach to hypertension. Investigating the factors that influence angiotensinogen levels, including sex hormones, may have important therapeutic implications. Methods: Plasma angiotensinogen and sex hormones levels were measured in 5,171 Multi-Ethnic Study of Atherosclerosis (MESA) participants. Linear models were employed to determine the associations of angiotensinogen with sex hormones, and mediation analysis was performed to evaluate the effect of HT on blood pressure (BP) and hypertension through angiotensinogen. Results: Angiotensinogen levels were significantly higher in postmenopausal women receiving HT (n=760) compared to women not receiving HRT (n=1,675) and in men (n=2,736). A positive association was present between angiotensinogen and estrogen levels that differed in magnitude between sexes and by HT status among postmenopausal women (women on HT: r=0.44, p< 0.0001; women not on HT: r=0.09, p=0.0002; and men: r= 0.07, p=0.0003). The type of HT formulation (estrogen or estrogen/progesterone) and its duration of use did not significantly affect angiotensinogen levels. HT indirectly increased systolic BP (β=1.24) and the odds of hypertension (OR=1.065) through its effect of increasing angiotensinogen. Conclusions: A positive association was present between angiotensinogen and estrogen levels that differed by HT status. HT impacts systolic BP and hypertension indirectly by increasing angiotensinogen. This study underscores the role of angiotensinogen in hypertension, and the complex relationship between HT and hypertension.

show abstract

Section: Methodsmentioning

confidence: 99%

“…However, therapies targeting the metabolism or reception of Ang peptides derived from angiotensinogen often lead to a compensatory pathway that limits therapeutic efficacy as monotherapy 2 . This necessitates the use of a combination with other classes of drugs to achieve adequate blood pressure control in many patients.…”

Section: Introductionmentioning

confidence: 99%

Circulating Levels of Angiotensinogen, Sex, and Hormone Therapy - The Multi-Ethnic Study of Atherosclerosis (MESA)

Lidani,

Trainor,

Buscaglia

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…[ 26 ] SNPs have been reported with a frequency ≥ 1% in at least one population. [ 27 ] Recently, SNPs in regions of coding or noncoding DNA and disease risk have been investigated for their interaction in the onset of cancer, [ 28 ] inflammatory diseases, [ 29 ] cardiovascular disease, [ 30 ] skin diseases, [ 31 ] anxiety disorders, [ 32 ] etc. Strategies used for SNP detection typically involve primer extension, hybridization, or enzyme cleavage.…”

Section: Biological Detectionmentioning

confidence: 99%

Sensing, Imaging, and Therapeutic Strategies Endowing by Conjugate Polymers for Precision Medicine

Shen,

Song,

Lin

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

Conjugated polymers (CPs) have promising applications in biomedical fields, such as disease monitoring, real‐time imaging diagnosis and disease treatment. As a promising luminescent material with tunable emission, high brightness and excellent stability, CPs are widely used as fluorescent probes in biological detection and imaging. Rational molecular design and structural optimization have broadened absorption/emission range of CPs, which are more conductive for disease diagnosis and precision therapy. This review provides a comprehensive overview of recent advances in the application of CPs, aiming to elucidate their structural and functional relationships. The fluorescence properties of CPs and the mechanism of detection signal amplification are firstly discussed, followed by an elucidation of their emerging applications in biological detection. Subsequently, CPs‐based imaging systems and therapeutic strategies are illustrated systematically. Finally, recent advancements in utilizing CPs as electroactive materials for bioelectronic devices are also investigated. Moreover, the challenges and outlooks of CPs for precision medicine are discussed. Through this systematic review, we hope to highlight the frontier progress of CPs and promote new breakthroughs in fundamental research and clinical transformation.This article is protected by copyright. All rights reserved

show abstract

“…This approach is attractive due to potential for fewer dangerous side effects, such as hyperkalemia, and potential for higher long-term efficacy due to avoidance of RAAS escape, where there is a rise in renin with long-term use of many first-line hypertensive therapies. 76,77 These longer-acting, subcutaneously administered medications, also offer a substantial benefit in addressing well-documented concerns about compliance with oral antihypertension therapies. However, there are also safety concerns associated with a long-acting antihypertensive agent with no existing antidotes, should reversibility be desired, for example, in case of sepsis or hypovolemia.…”

Section: Angiotensinogen Blockade With Sirna and Antisense Therapiesmentioning

confidence: 99%

Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy

Magavern,

Kapil,

Saxena

et al. 2024

ATVB

View full text Add to dashboard Cite

Hypertension is a prevalent public health problem, contributing to >10 million deaths annually. Though multiple therapeutics exist, many patients suffer from treatment-resistant hypertension or try several medications before achieving blood pressure control. Genomic advances offer mechanistic understanding of blood pressure variability, therapeutic targets, therapeutic response, and promise a stratified approach to treatment of primary hypertension. Cyclic guanosine monophosphate augmentation, aldosterone synthase inhibitors, and angiotensinogen blockade with silencing RNA and antisense therapies are among the promising novel approaches. Pharmacogenomic studies have also been done to explore the genetic bases underpinning interindividual variability in response to existing therapeutics. A polygenic approach using risk scores is likely to be the next frontier in stratifying responses to existing therapeutics.

show abstract

Angiotensinogen

Cited by 15 publications

References 99 publications

Circulating Levels of Angiotensinogen, Sex, and Hormone Therapy - The Multi-Ethnic Study of Atherosclerosis (MESA)

Circulating Levels of Angiotensinogen, Sex, and Hormone Therapy - The Multi-Ethnic Study of Atherosclerosis (MESA)

Sensing, Imaging, and Therapeutic Strategies Endowing by Conjugate Polymers for Precision Medicine

Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy

Contact Info

Product

Resources

About